| Literature DB >> 30702807 |
Jakub Modranka1, Jiahong Li1, Anastasia Parchina1, Michiel Vanmeert1, Shrinivas Dumbre1, Mayla Salman2, Hannu Myllykallio2, Hubert F Becker2,3, Roeland Vanhoutte4, Lia Margamuljana1, Hoai Nguyen1, Rania Abu El-Asrar1, Jef Rozenski1, Piet Herdewijn1, Steven De Jonghe1,5, Eveline Lescrinier1.
Abstract
Since the discovery of a flavin-dependent thymidylate synthase (ThyX or FDTS) that is absent in humans but crucial for DNA biosynthesis in a diverse group of pathogens, the enzyme has been pursued for the development of new antibacterial agents against Mycobacterium tuberculosis, the causative agent of the widespread infectious disease tuberculosis (TB). In response to a growing need for more effective anti-TB drugs, we have built upon our previous screening efforts and report herein an optimization campaign of a novel series of inhibitors with a unique inhibition profile. The inhibitors display competitive inhibition toward the methylene tetrahydrofolate cofactor of ThyX, enabling us to generate a model of the compounds bound to their target, thus offering insight into their structure-activity relationships.Entities:
Keywords: antibiotics; benzo[b][1,4]oxazine; drug discovery; tuberculosis
Mesh:
Substances:
Year: 2019 PMID: 30702807 DOI: 10.1002/cmdc.201800739
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466